Navigation Links
Seroquel Sustained Release Schizophrenia Data Presented at ECP,Congress in Madrid

perienced a significantly reduced risk of relapse (risk reduction of 87 percent, p<0.0001), and a significantly longer time to relapse, compared with those on placebo. Differences in relapse rate between active treatment and placebo were large enough to require the study to be stopped early, in accordance with the study protocol. In the SEROQUEL® sustained release group, the estimated risk of relapse after six months was 14.3 percent versus 68.2 percent in the placebo group (p<0.0001). Hospitalisation due to worsening of schizophrenia was required by 8.3 percent of patients on placebo, but was not needed for any patients taking SEROQUEL® sustained release formulation.

Professor Rene Kahn, Professor and Chair of the Department of Psychiatry and Head of the Division of Neuroscience at the University Medical Center, Utrecht, said: “In these studies SEROQUEL® sustained release formulation showed its potential as a once-daily treatment for both acute and clinically stable schizophrenia. Statistical significance on the primary endpoint was seen at doses between 400 and 800 mg/day and patients achieved that range within two days of starting treatment – that is an advantage over original formulation quetiapine, where the initial dose escalation is not so simple. In mental healthcare, striving for treatment that is simpler and more practical is an important objective for patients and doctors.”

In both studies, somnolence and dizziness were the most common adverse events with SEROQUEL® sustained release formulation and these were generally mild or moderate, transient, and did not lead to withdrawal from the trials. The incidence of extrapyramidal adverse events was similar to placebo (EPS-related adverse events were seen in 5.1 percent of patients taking placebo versus 2.7 percent [400mg], 8.0 percent [600mg] and 4.1 percent [800mg] of patients taking SEROQUEL® sustained release formulation in the acute study).

Other
'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
2. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
3. OREXIGEN Therapeutics Announces Sustained-Release Formulation of Zonisamide Shows Improved Tolerability When Compared to Immediate Release Formulation
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
7. Copaxone Treatment over Two Years after Short Term Induction with Mitoxantrone Provided Sustained Benefits to Active Relapsing-Remitting Multiple Sclerosis Patients
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
10. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
(Date:10/1/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... agreement with Patterson Veterinary Supply. Patterson ... of Abaxis veterinary products throughout the United ...
(Date:10/1/2014)... DIEGO , Oct. 1, 2014  ResMed (NYSE: ... sleep and the first company to design complete sleep apnea ... educate women about the importance of a good night,s sleep. ... will challenge the myth that feeling tired is just part ... understand that sleep is a critical pillar of health, essential ...
(Date:10/1/2014)...   Cypher Genomics, Inc., the genome informatics ... Ravenel as chief technology officer. Ravenel has more ... and a proven track record of designing and architecting ... has been recognized as a top designer and architect ... industry-wide for delivering innovative products that operate at scale ...
Breaking Medicine Technology:Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 2Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 3Abaxis Announces Distribution Agreement with Patterson Veterinary Supply 4ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2
... Romark Laboratories, L.C., a,privately-owned biopharmaceutical company, today ... clinical trial to evaluate the safety and,efficacy of ... in,U.S. patients with chronic hepatitis C genotype 1 ... of care therapy (peginterferon and,ribavirin). The company expects ...
... Urologist Presents OrBIT Study Results Comparing Percutaneous, Tibial Nerve ... ... Meeting, MINNEAPOLIS, May 21 Uroplasty, Inc. (Amex:,UPI), ... proprietary products for the treatment of voiding dysfunction,today highlighted ...
Cached Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 2Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System 3
(Date:10/2/2014)... Steven Reinberg HealthDay Reporter ... to a major highway may raise your risk for high ... 5,000 postmenopausal women, those who lived within 109 yards of ... developing high blood pressure than women living at least half ... this study highlight the importance of our physical environment on ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... and the District of Columbia now have a total of ... that has been infecting children since the summer, U.S. ... virus have died in recent weeks, but it,s not clear ... those deaths, officials said. Health officials are also trying ...
(Date:10/1/2014)... An international team of scientists has shown that more ... treated with existing drugs. , The study found that ... cancers with a genetic mutation that is present in ... JAK inhibitors are currently used, or are in clinical ... and myeloproliferative disorders. , Bowel cancer is the second-most ...
(Date:10/1/2014)... Patients with increased inflammation, including those receiving cytokines ... of depression. For example, a 6-month treatment course ... infection causes depression in approximately 30% of patients. ... as fish oil, have a long list of ... disease and reducing triglyceride levels. These nutritional compounds ...
(Date:10/1/2014)... October 01, 2014 Marriagelifeinsurance.com has ... life insurance for retired couples. , Senior citizens ... financial security for their loved ones. A joint policy ... insured persons pass away. , Life insurance can ... life insurance can even be purchased online, as the ...
Breaking Medicine News(10 mins):Health News:Living Near a Highway May Be Bad for Your Blood Pressure 2Health News:Living Near a Highway May Be Bad for Your Blood Pressure 3Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2
... News) -- Bats and dolphins aren,t the only mammals that ... identify objects and navigate unfamiliar surroundings. Researchers have found ... published online May 25 in PLoS ONE , found ... the faint returning echoes, blind people were able to map ...
... drug that is commonly used to prevent organ transplantation ... finding from UNC scientists was reported in the May ... of surgery, said, " We now have a rationale ... reduces breast cancer growth in humans. Since Tacrolimus is ...
... converging in patient care at a faster pace than ... point-of-care health technologies like telemedicine to medical robots performing ... What,s next? Ask NJIT Distinguished Professor Atam Dhawan, ... Albert Dorman Honors College, chair of the the ...
... , THURSDAY, May 26 (HealthDay News) -- Caffeine, a ... nausea, anxiety and depression. Now, new research reveals that caffeine ... pregnant. By analyzing fallopian tubes in mice, researchers found ... from the ovaries through the fallopian tubes and into the ...
... News)-- Lists of the side effects for prescription medications ... an average of 70 per medication, a new study reports. ... and consumers of potential hazards, but this expansion may have ... health concerns, say the study authors, who argue the information ...
... that has been on the market for decades to treat ... be a possible therapy for vascular diseases, including atherosclerosis and ... Previously, researchers discovered that retinoids commonly used natural ... vascular disease by spurring into action a very particular segment ...
Cached Medicine News:Health News:Blind People May Be Able to Use Echoes to Identify Objects 2Health News:Common transplant drug inhibits breast cancer growth, UNC laboratory study shows 2Health News:5 new hot spots where medicine and technology will converge 2Health News: Caffeine May Interfere With Fertility in Women 2Health News:Lists of Prescription Meds' Side Effects Keep Growing: Study 2Health News:Multitasking meds: Scientists discover how drug for leukemia, psoriasis, may tackle vascular disease 2Health News:Multitasking meds: Scientists discover how drug for leukemia, psoriasis, may tackle vascular disease 3
Foldable Hydrophilic IOL with UV Absorber....
The STAAR ELASTIC LENS®, is a single piece silicone lens to be placed completely in the capsular bag....
... Engineers at Pfizer used wavefront sensing ... Optic Technology. Innovative TECNIS features a patented ... spherical aberration, which compensates for the positive ... result, TECNIS is the first and only ...
... PhacoFlexII SI30NB is foldable silicone ... it's patients. It is used ... SI30NB is indicated for primary ... of aphakia in adults (over ...
Medicine Products: